The Ontario Hereditary Cancer Research Network is assembling a province-wide registry for research-consented individuals who have received hereditary cancer gene testing.

The recommendation makes a second drug available in England for treating transthyretin amyloidosis with cardiomyopathy.

The acquisition follows Repare's decision this year to deprioritize its lead programs and lay off 75 percent of its workforce.

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

The companies will submit data showing zipalertinib resulted in a 35.2 percent response rate in patients with exon 20 mutations.

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

"The CIRM grant will enable ReviR Therapeutics to further develop their preclinical candidate through rigorous preclinical studies and into clinical trials, with an initial goal to ensure that the ...